Rating Worth Watching: Valeant Pharma (NYSE:VRX) Loses a Vote of Confidence From Mizuho Securities. What to Expect?

November 23, 2016 - By Hazel Jackson

Rating Worth Watching:  Valeant Pharma (NYSE:VRX) Loses a Vote of Confidence From Mizuho Securities. What to Expect?

Valeant Pharma (NYSE:VRX) Downgrade

In a a research report released on 23 November, Mizuho Securities has lowered Valeant Pharma (NYSE:VRX) stock to a “Underperform” and has set an estimated 12-month target price per share at $11.0. VRX’s old rating was “Neutral”.

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) Ratings Coverage

Out of 23 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 8 rate it a “Buy”, 2 “Sell”, while 13 “Hold”. This means 35% are positive. $310 is the highest target while $23 is the lowest. The $107.53 average target is 512.71% above today’s ($17.55) stock price. Valeant Pharmaceuticals Intl has been the topic of 79 analyst reports since July 21, 2015 according to StockzIntelligence Inc. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) earned “Market Perform” rating by BMO Capital Markets on Wednesday, June 29. Goldman Sachs downgraded the shares of VRX in a report on Monday, November 2 to “Neutral” rating. Deutsche Bank maintained it with “Hold” rating and $24 target price in Monday, November 14 report. The firm has “Hold” rating by Canaccord Genuity given on Wednesday, March 16. Rodman & Renshaw maintained the stock with “Buy” rating in Monday, April 11 report. The stock has “Underperform” rating given by Wells Fargo on Friday, February 19. Guggenheim maintained it with “Buy” rating and $195.0 target price in Friday, November 6 report. The firm has “Sector Outperform” rating given on Tuesday, October 20 by Scotia Capital. Morgan Stanley maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) rating on Thursday, November 10. Morgan Stanley has “Overweight” rating and $25.0 price target. The rating was maintained by Rodman & Renshaw on Wednesday, March 16 with “Buy”.

About 114,699 shares traded hands. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 46.54% since April 21, 2016 and is downtrending. It has underperformed by 51.87% the S&P500.

Insitutional Activity: The institutional sentiment increased to 0.88 in Q2 2016. Its up 0.02, from 0.86 in 2016Q1. The ratio improved, as 88 funds sold all Valeant Pharmaceuticals Intl Inc shares owned while 97 reduced positions. 52 funds bought stakes while 107 increased positions. They now own 217.59 million shares or 18.89% less from 268.27 million shares in 2016Q1.

Wolverine Asset Mgmt Limited Liability Corporation holds 0.05% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 162,892 shares. Sandy Spring Comml Bank holds 0% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 306 shares. Teacher Retirement System Of Texas has invested 0.03% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Trust Of Vermont last reported 2,000 shares in the company. Kcg Hldg Incorporated accumulated 97,627 shares or 0.04% of the stock. Kemnay Advisory Svcs has 0.01% invested in the company for 690 shares. Fiera Cap accumulated 734,419 shares or 0.08% of the stock. Intact Inv Inc has invested 0.18% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Qs Ltd holds 85,789 shares or 0.01% of its portfolio. Renaissance Tech Limited Liability Corp has invested 0% of its portfolio in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Wasatch Advisors accumulated 18,238 shares or 0.01% of the stock. Chou Assocs Mgmt Inc holds 976,843 shares or 2.66% of its portfolio. Commerzbank Aktiengesellschaft Fi last reported 231,752 shares in the company. Riggs Asset Managment reported 14,044 shares or 0.15% of all its holdings. Rock Springs Mngmt Ltd Partnership has 66,100 shares for 0.1% of their US portfolio.

Insider Transactions: Since June 9, 2016, the stock had 2 insider purchases, and 0 insider sales for $5.04 million net activity. 4,000 shares were bought by KARABELAS ARGERIS N, worth $98,600 on Thursday, August 11. The insider PAPA JOSEPH C bought $4.94M.

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company has a market cap of $5.92 billion. The Firm is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It currently has negative earnings. It operates through two divisions: Developed markets and Emerging markets.

According to Zacks Investment Research, “Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant’s development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.”

VRX Company Profile

Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Firm operates through two divisions: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products and medical devices.

More notable recent Valeant Pharmaceuticals Intl Inc (NYSE:VRX) news were published by: Business.Financialpost.com which released: “Valeant Pharmaceuticals International needs to do a lot more than just cry …” on November 21, 2016, also Fool.com with their article: “Why Valeant Pharmaceuticals Intl Inc Stock Is Slumping Today” published on November 08, 2016, Profitconfidential.com published: “Valeant Pharmaceuticals Intl Inc: VRX Stock Rises Again” on November 10, 2016. More interesting news about Valeant Pharmaceuticals Intl Inc (NYSE:VRX) were released by: Investorplace.com and their article: “Valeant Pharmaceuticals Intl Inc (VRX) Stock Owners Should Ask Tougher Questions” published on November 15, 2016 as well as Fool.com‘s news article titled: “3 Figures in Focus When Valeant Pharmaceuticals Intl. Inc. Reports Its Q3 Results” with publication date: November 01, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>